- Inventiva (NASDAQ:IVA) has signed a €50 million bullet credit facility agreement with the European Investment Bank.
- The company plans to use the facility for its preclinical and clinical pipeline, including to help fund a portion of its Phase 3 clinical trial of lanifibranor in patients with non-alcoholic steatohepatitis (NASH).
- Related: Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor.
- The facility is divided into two tranches of €25 million each. The disbursement of Tranche A is subject to the completion of certain conditions precedent specified in the credit facility agreement.
- Tranche B is subject to the full drawdown of Tranche A and the achievement of certain conditions precedents.
- It is expected that the reimbursement of the interests and capital of this credit facility will happen after the publication of the headline results of part 1 of the Phase 3 trial of lanifibranor in patients with NASH, expected in 2H 2024.
- Price Action: IVA shares are up 3.40% at $9.10 during the market session on the last check Monday.
